Syncom Formulation (India) (BOM:524470) Debt-to-Equity : N/A (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Syncom Formulation (India) Debt-to-Equity?

Syncom Formulation (India)'s Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. Syncom Formulation (India)'s Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. Syncom Formulation (India)'s Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₹0 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Syncom Formulation (India)'s Debt-to-Equity or its related term are showing as below:

BOM:524470' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.08 Max: 0.4
Current: 0.3

During the past 13 years, the highest Debt-to-Equity Ratio of Syncom Formulation (India) was 0.40. The lowest was 0.02. And the median was 0.08.

BOM:524470's Debt-to-Equity is ranked worse than
50.7% of 852 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs BOM:524470: 0.30

Syncom Formulation (India) Debt-to-Equity Historical Data

The historical data trend for Syncom Formulation (India)'s Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syncom Formulation (India) Debt-to-Equity Chart

Syncom Formulation (India) Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

Get a 7-Day Free Trial

0.07

0.02

0.33

0.26

0.33

Syncom Formulation (India) Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															N/A	0.33	N/A	0.30	N/A

Competitive Comparison of Syncom Formulation (India)'s Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Syncom Formulation (India)'s Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Syncom Formulation (India)'s Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Syncom Formulation (India)'s Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Syncom Formulation (India)'s Debt-to-Equity falls into.

Syncom Formulation (India) Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Syncom Formulation (India)'s Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(831.815	+	0)	/	2560.147
	=	0.32

Syncom Formulation (India)'s Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	0
	=	N/A

Syncom Formulation (India) (BOM:524470) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Syncom Formulation (India) Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Syncom Formulation (India)'s Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Syncom Formulation (India) (BOM:524470) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syncom Formulation (India) Ltd (BOM:524470) » Definitions » Debt-to-Equity

Traded in Other Exchanges

SYNCOMF:India

Address

207, Saket Nagar, Near Saket Club, Indore, MP, IND, 452018

Website

https://www.sfil.in

Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.

Syncom Formulation (India) (BOM:524470) Headlines

No Headlines